An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 [iratumumab] in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma.

Trial Profile

An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 [iratumumab] in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Iratumumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2009 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Jul 2007 Status changed from recruiting to completed.
    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top